Here is a post from another board I think you will appreciate. One of the most liked posts of all time . Viewed a ton. Thanks to mightycvdy!:

Bill Gates mentions accelerated rollout of HIV cure

For those who haven't been following closely, CYDY recently added HIV expert Dr. Max Lataillade as "Senior Vice President and Head of Clinical Development". Details here:
https://www.cytodyn.com/newsroom/press-releas...enior-vice

On the very same day that Dr. Max updated his Linkedin page by adding his new role at CYDY, Dr. Max also announced his new role as "Head of HIV Drug Development Bill & Melinda Gates Foundation". Details here:
https://www.linkedin.com/in/maxlataillade/

This is worth reading (key excerpt: "This led the researchers to determine that stopping HIV from using the CCR5 receptor to infect donor cells is also needed for a cure to occur."
https://news.ohsu.edu/2023/05/25/ohsu-researc...-in-people

Also worth reading:
https://www.biospace.com/cytodyn-highlights-n...leronlimab

And:
https://www.cytodyn.com/newsroom/press-releas...eronlimabs

Now check out this (new) two-minute video interview where Bill Gates talks about the Gates foundation currently developing a cure for HIV and the possibility of rolling it out at an accelerated pace:

https://www.wsj.com/politics/policy/bill-gate...g-e54fc20d

Hopefully CYDY's Leronlimab will play a major role in the HIV Cure that the Gates foundation is developing and planning to rollout in the near future. In addition to saving countless lives, this is noteworthy (per ChatGPT): "According to recent market reports, the global HIV drugs market is currently valued at around $33 billion and is expected to reach approximately $49.68 billion by 2032, growing at a CAGR of 4.3% with combination-class drugs dominating the market share; this indicates a substantial market for HIV treatments, although a true "cure" is not yet widely available."

Excerpted from CYDY's website:
"...Leronlimab is being studied for HIV... Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. We believe this mechanism of action, of binding competitively to the CCR5 receptor, differentiates leronlimab from all other CCR5 antagonists."

"Leronlimab belongs to a class of HIV therapies known as viral entry inhibitors that block HIV from entering and infecting healthy cells. In illustrating the importance of CCR5 in HIV, individuals that lack CCR5 expression due to a natural genetic mutation are naturally resistant to HIV infection. Today, six people have been cured of HIV who were given transplanted cells either completely or partially deficient in the CCR5 receptor."

"CytoDyn is currently evaluating the potential role of leronlimab in achieving an HIV cure."

I remain... #BULLISH

PSA:


All major U.S. stock markets will be closed on Monday January 20, in observance of Martin Luther King Jr. Day.

Sorry when you make such a blanket statement such as "But none of it was true, was it?" I must completely disregard your posts.

There is significant CYDY news coming. Some might even be shocked.

For those interested in reading posts from MGK_2:

https://www.reddit.com/r/Livimmune/comments/1i33nxw/games_people_play/

10Q

https://www.cytodyn.com/investors/sec-filings/all-sec-filings/content/0001558370-25-000207/0001558370-25-000207.pdf

very simplistic viewpoint you promote. I can think of several reasons why the stock could move besides the initiaton of a human trial if that is what you mean.

From MGK_2:

https://www.reddit.com/r/Livimmune/comments/1i13186/off_ramp/

SH's did vote her and everyone else back in recently. She did get fewer votes but I doubt she gave it much of a thought. Perhaps I'm wrong. The board members have a number of responsibilities although leading fundraising campains is probably not high on the list if at all. That would fall to CEO/CFO and perhaps Business Ops.

Yes the PPS sucks and that has happened during Tanya's and everybody elses tenure.

I don't know whether Tanya's relationship with Paulson hurts CYDY. I believe raising money via Fife and even private investors sucks at these PPS levels and needs to be replaced with better options by later this year.

Pretty sure all those investors are interested in a higher PPS. Tanya is/was put there to head up fixing CYDY's legal issues. Probably with a significant help from Paulson. Welch wants CYDY to succed more than anyone.

Having said that I don't disagree a money person would be a tremendous asset to CYDY. Whether that be a new COB or eventually as President/CEO might be up for debate.

From MGK_2 at Reddit:

The GenoType of Leronlimab Leads to the PhenoType of the Leronlimab Disease Pattern

https://www.reddit.com/r/Livimmune/comments/1htj36s/the_genotype_of_leronlimab_leads_to_the_phenotype/

Facts are facts and shouldn't be hidden. Some might even appreciate the opportunity presented in part due to NP's behavior. You can "warn any newbies" all you want but I think new investors will be much more interested in current events moving forward.

https://www.cytodyn.com/newsroom/press-releases/detail/633/december-2024-letter-to-shareholders

Like it or not Charlie used leronlimab with great success.
As far as celebrities go, Charlie has a incredible career. I'd be thrilled to have the royalty payments alone.

At these prices you are paying for what you have gotten. No argument there. Of course that isn't the point. Stocks are purchased with the expectation of price appreciation in the future. I have a bunch of blue chip dividend paying stocks. If I or anyone else wants to buy a 12 cent speculative stock that may take time to bear fruit or not , why should anyone have a problem with them doing so.

He was and seemed to have good results. That was a good while back. Your post suggests he is currently taking the drug. What makes you think he is still on leronlimab? BTW, leronlimab.has been used on 1200 plus patients as of now.

Very long but interesting post from another board. Grab a drink and take a load off:

https://www.reddit.com/r/Livimmune/comments/1hozje2/hot_month_ahead/

Found on another site:

Leronmilab is among the category of drugs submitted to the Recover program. Next review is going to be in mid January

https://fnih.org/our-programs/recover-tlc-will-advance-long-covid-research/recover-tlc-therapeut

Regarding one of leronlimab's possible indications:

The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases.

Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031*—a clear indicator of oncology's rapid growth and critical importance.*

I appreciate your comment about the lack of upwards movement here but…I think that concern would be more valid after the next couple of news items come out after the first of the year and there’s still no PPS appreciation.

This post is worth reposting:
https://www.cytodyn.com/newsroom/press-releases/detail/633/december-2024-letter-to-shareholders

Anyone want to speculate on what the next CYDY announcement may be regarding and when it could be released?

I sent 2 requests wirh no response so far. I'm not sure if IH has a staffing problem or what.

https://journals.lww.com/co-hivandaids/abstract/2025/01000/stem_cell_transplantation_and_allogeneic_immunity_.14.aspx
Co-authored by 2 CYDY notables

My understanding and I may be misinformed, the offer was arounf $10 million. Why would Nostrum turn down such a sum given the situation they are/were in?

There is a potential asset woth minimally hunfreds of millions to Nostrum/CRXM and between the 2 companies they can't make a deal for one or the other to be purchased outright or raise $20-25 million to get to the finish line within a year or two?

Something isn't right with this picture.

Didn't CRXM try to buy Nostrum out fairly recently and Nostrum turned down a significant amount of money?

Altitrade Partners:

The below post was from a few months ago. Has your thinking changed any as time has passed and we are at years end? I personally have one of my family members wondering if they should take a tax loss at this point on their CRXM position.

Altitrade Partners

Re: bentleyt post# 6166

Friday, September 06, 2024 9:40:40 AM

Post#
6167
of 6188
It depends on three things:

1. They can obtain funding for a Phase 3 clinical trial of GeneRx.
2. They get a favorable outcome and FDA approval of the drug.
3. They can attract a Big Pharma company to purchase the drug.

I doubt that this company's shares will ever trade again. Instead, CRXM will likely implement an exit strategy for its shareholders based on the above, where the shareholders receive a portion of the proceeds based on any sale of GeneRx.

As I have often said, shareholders should view this as an investment in a private company.
"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident." ~ Arthur Schopenhauer

Would someone please sticky the latest shareholder letter to the board. Thank you!

It was always a long shot to work as solo treatment. Nothing really does.It is a terrible cancer. Think we will find leronlimab is going to be used in combo in a number of indications given what positive effects we know so far.

https://www.cytodyn.com/newsroom/press-releases/detail/633/december-2024-letter-to-shareholders

Anything on the funding?

I wish everyone a great holiday and Happy New Year!

Good grief, you would think a CEO would have the decency to provide an update to shareholders at the end of the year.

I thought you promised to leave the board?

Anyway, I am amazed CYDY supporters can't give the naysayers their due. They deserve to be congratulated and allowed their moment in the sun.

I never shorted CYDY but I can clearly see why they did.

OTOH NP and everyone important around him enabling his ways are gone. Leronlimab should have an approval if not for the NP/KK/Amarex debacle. Very unfortunate for shareholders.

As we move into 2025 things are looking a bit brighter althiugh there are still plenty of unknowns. Some of these unknowns will be cleared up quite soon and more fairly soon. I've seen posts from some of the more objective naysayers turn guaredly optimistic to supportive of the changes made in the last year and the track Dr JL has presented.

We will see what happens in the coming months. In the meantime I wish everyone has a blessed Christmas and safe New Year. Be kind to each other while you make your arguments for and against. I fear an increasing number of people are losing the ability to have opoosing views without reacting in unhealthy ways and at times outright dangerously.

I expect a company update in the next couple of weeks or so. It should give investors plenty to think through and discuss.

January date release:

Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment

https://www.sciencedirect.com/science/article/pii/S1043661824004894?via%3Dihub

Leronlimab mention

Max Lataillade LinkedIn CYDY Sr VP

I am thrilled to share that I have joined the Bill & Melinda Gates Foundation as the new Head of HIV Drug Development. This is a profound honor, as I have long admired the Foundation’s unwavering commitment to improving global health outcomes and its mission to develop sustainable, scalable solutions to eliminate the HIV epidemic.

In this unique role, overseeing both global HIV drug strategy and drug development, I am eager to leverage my leadership and extensive experience in drug development within the biotech and pharmaceutical industries to accelerate the delivery of innovative solutions to one of the world’s most pressing health challenges: preventing HIV transmission. Through this work, I aim to move us closer to the ultimate goal of HIV eradication.

I am particularly excited about the opportunity to work with brilliant colleagues, collaborate with partners around the world, champion science-driven ideas, and lead strategies at the Foundation to develop long-acting antiretroviral options for HIV prevention and treatment in high-burden countries.

Together, we can make a lasting impact on the fight against HIV and help pave the way for a healthier, more equitable future for all.

Post from another board. Good list of 2024 accomplishments for CYDY:

https://www.reddit.com/r/Livimmune/comments/1h0enwb/adapting_and_building/

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
Download as PDFNovember 25, 2024 8:30am EST
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Richard Pestell, M.D., Ph.D., has been appointed as Lead Consultant, Preclinical and Clinical Oncology. Dr. Pestell will lead the Company’s research and development strategy in oncology and utilize his expertise and vast network to further CytoDyn’s clinical evaluation of the capabilities for leronlimab in cancer treatment.

Dr. Pestell brings over three decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He is currently the President of the Pennsylvania Cancer and Regenerative Medicine Research Center, a part of the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Prior to this role, he spent a decade at Thomas Jefferson University in Philadelphia, Pennsylvania, serving as Director of the Sidney Kimmel Cancer Center, Chairman of the Department of Cancer Biology and Executive Vice President. Dr. Pestell’s work has been published in over 600 publications, and his research has been credited with well over 95,000 citations. He previously served as Vice Chairman of the Board, and Chief Medical Officer (CMO), spearheading the Company’s successful effort to obtain Fast Track Designation from the FDA for the use of leronlimab in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. In addition, Dr. Pestell was instrumental in designing and initiating CytoDyn’s Phase 1b/2 clinical trial in that indication.

“I’m thrilled to welcome Dr. Pestell back to the CytoDyn team. I have known Dr. Pestell personally for a number of years, and I look forward to leveraging his insights and expertise to advance our clinical development pipeline in oncology,” said Dr. Jacob Lalezari, CEO. “As we continue to prioritize the development of leronlimab in oncology, Dr. Pestell’s expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”

Dr. Pestell added, “I am confident that leronlimab holds significant promise for improving patient care and expanding treatment options in oncology. I am eager to support the Company’s efforts to advance our clinical development pipeline and leverage the potential of leronlimab to improve outcomes for cancer patients.”

Dr. Pestell holds a medical degree from the University of Western Australia, and a Ph.D. from the University of Melbourne, Howard Florey Institute. He conducted clinical training in oncology and endocrinology and was inducted as a Fellow of the Royal Australian College of Physicians. His postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital with Dr. Larry Jameson focused on endocrine oncology. He completed his executive MBA at New York University’s Stern School of Business in 2011. Dr. Pestell has received numerous awards for his research discoveries including elected membership to ASCI (American Society of Clinical Investigation), Elected Member of the Royal Society of Medicine, Elected Fellow of the American Association for the Advancement of Science, the RD Wright Medallion, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, HonorisCausa, from the University of Melbourne and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award). Dr. Pestell received the Order of Australia (AO) in 2019 from Queen Elizabeth II and was elected as a Member of the Academia Europaea in 2024.

https://einsteinmed.edu/departments/medicine/divisions/pulmonary-medicine/patient-care/pulmonary-failure-lung-transplant/

Mention of leronlimab

Something Leronlimab may have an indication for in the future:

Fernando Valenzuela’s cause of death has been determined after the Dodgers legend died last month at the age of 63.

According to his death certificate, the broadcaster and former pitched died due to decompensated alcoholic cirrhosis and nonalcoholic steatohepatitis cirrhosis.

It looks like Tanya Urbach’s current employer, Eagle Bay Advisors may have purchased 162,000 shares of Cytodyn per a 13F-HR form being filed.

Mentions CYDY (CC chemokine receptor type 5 market)
https://www.globenewswire.com/news-release/2024/11/07/2976822/0/en/CC-Chemokine-Receptor-Type-5-Market-Research-Report-2024.html

Fibrosis split from MASH at some point on the pipeline chart:

https://www.cytodyn.com/pipeline

https://www.targetedonc.com/view/fda-clears-phase-2-trial-of-leronlimab-for-microsatellite-stable-crc

Holy cow. PACV kept that info quiet as possible. How can that be for a public company. How is that not material information?